Cell Therapy News/Articles, page-5005

I am leaning towards what @lindym said Post #: 46062678

The idea that by the time we get an interim read out, full or nearly full enrolment (300) will have been achieved due to the recent rise in cases and more hospitals recruiting. Essentially much speedier recruitment in the later stages of trial.

That way we may have sufficient data to move towards approval and use of remestemcel-L in the short term, but still get full trial data 2-3 months later. No need to halt trial. Maybe wishful thinking on my part but that would be ideal.